Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators

Title:Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators

Volume: 16 Issue: 7

Author(s): Malik Hamaidia, Bernard Staumont, Bernard Duysinx, Renaud Louis and Luc Willems

Affiliation:

Keywords: Cancer, Epigenetic inhibitors, Histone deacetylase, Immunotherapy, Malignant pleural mesothelioma.

Abstract: In the absence of a satisfactory treatment of malignant pleural mesothelioma (MPM), novel therapeutic strategies are urgently needed. Among these, immunotherapy offers a series of advantages such as tumor specificity and good tolerability. Unfortunately, MPM immunotherapy is frequently limited by incomplete cell differentiation or feedback loop regulatory mechanisms. In this review, we describe different components of the innate immune system and discuss strategies to improve MPM immunotherapy by using epigenetic modulators.

Cite this article as:

Hamaidia Malik, Staumont Bernard, Duysinx Bernard, Louis Renaud and Willems Luc, Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators, Current Topics in Medicinal Chemistry 2016; 16 (7) . https://dx.doi.org/10.2174/1568026615666150825141152